Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)
This study has been completed.
Merck Sharp & Dohme Corp.
First Posted: March 10, 2008
Last Update Posted: February 23, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers. This group of drugs blocks one of the ways HIV enters T-cells (the cells that fight infection). Previous studies in HIV treatment-experienced patients have shown that vicriviroc is safe and effective. The purpose of this study is to determine the effect of vicriviroc on HIV RNA levels in cerebrospinal fluid (CSF).
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Effect of Vicriviroc on HIV RNA Levels in Cerebrospinal Fluid|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck Sharp & Dohme Corp.:
Primary Outcome Measures:
- Change in HIV RNA levels in CSF [ Time Frame: Pretreatment and Week 2 visits ]
Secondary Outcome Measures:
- Proportion of subjects achieving CSF HIV RNA <50 copies/mL [ Time Frame: Week 2 ]
|Study Start Date:||March 2008|
|Study Completion Date:||March 2010|
|Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
Experimental: VCV + Failing HAART
Vicriviroc plus failing highly-active antiretroviral therapy
One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
Other Name: Vicriviroc maleate, SCH-D, SCH 417690, VCV
This is a nonrandomized, open-label, multicenter study to investigate the HIV antiviral response in CSF when vicriviroc is added for 2 weeks to the subject's failing antiretroviral background regimen. The primary efficacy endpoint of this study is the mean change in log10 CSF HIV RNA from baseline at Week 2. The secondary efficacy endpoint is the proportion of subjects achieving CSF HIV RNA <50 copies/mL at Week 2. At Week 2, the subject's background regimen will be optimized and vicriviroc continued up to Week 24. After completing Week 24 of the study, subjects will be offered the option to continue on open-label VCV 30 mg once daily, if appropriate, until commercially available or until the sponsor terminates the clinical development of VCV. Subjects who discontinue vicriviroc for any reason will be requested to participate in long-term follow up.
Contacts and Locations
No Contacts or Locations Provided